Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Steven Feldman MD, PhD

Steven R. Feldman MD, PhD

Professor of Dermatology, Pathology & Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Dr. Steve Feldman is Professor of Dermatology, Pathology & Public Health Sciences at the Wake Forest University School of Medicine. His research studies into patients’ adherence to topical treatments are transforming how physicians understand and manipulate patients’ use of treatment for chronic skin diseases. Dr. Feldman was the founder of, an online doctor rating/patient feedback website, and he is chief technology officer for Causa Research, a company that provides adherence improving services to industry. Feldman has authored over 600 peer reviewed medical articles. Dr. Feldman is a regular columnist for PM360 on adherence and author of the books Compartments and Practical Ways to Improve Patients’ Treatment Outcomes.


Dr. Steven Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He is founder and majority owner of and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.